These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 17169252)

  • 21. High-density lipoprotein levels and risk of cardiovascular events: a review.
    Mureddu GF; Brandimarte F; De Luca L
    J Cardiovasc Med (Hagerstown); 2012 Sep; 13(9):575-86. PubMed ID: 21986488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update on the discovery and development of cholesteryl ester transfer protein inhibitors for reducing residual cardiovascular risk.
    Mantlo NB; Escribano A
    J Med Chem; 2014 Jan; 57(1):1-17. PubMed ID: 23941686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-Density Lipoprotein-Targeted Therapy and Apolipoprotein A-I Mimetic Peptides.
    Uehara Y; Chiesa G; Saku K
    Circ J; 2015; 79(12):2523-8. PubMed ID: 26548857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. No cardiovascular benefit with evacetrapib - is this the end of the road for the 'cetrapibs'?
    Doggrell SA
    Expert Opin Pharmacother; 2017 Oct; 18(14):1439-1442. PubMed ID: 28799819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The role of the high-density lipoprotein (HDL) particle in atherogenesis and potential methods to increase HDL concentrations].
    Birjmohun RS; van der Steeg WA; Stroes ES; Kastelein JJ
    Ned Tijdschr Geneeskd; 2006 Oct; 150(41):2245-50. PubMed ID: 17076358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin).
    Khera AV; Demler OV; Adelman SJ; Collins HL; Glynn RJ; Ridker PM; Rader DJ; Mora S
    Circulation; 2017 Jun; 135(25):2494-2504. PubMed ID: 28450350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [HDL and CETP in atherogenesis].
    Pöss J; Böhm M; Laufs U
    Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk.
    Farnier M
    Curr Cardiol Rep; 2016 Jul; 18(7):65. PubMed ID: 27216845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication.
    van de Woestijne AP; van der Graaf Y; Liem AH; Cramer MJ; Westerink J; Visseren FL;
    J Am Coll Cardiol; 2013 Nov; 62(20):1834-41. PubMed ID: 23948286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia.
    Le Goff W; Guerin M; Chapman MJ
    Pharmacol Ther; 2004 Jan; 101(1):17-38. PubMed ID: 14729390
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Importance of HDL cholesterol in atherothrombosis: how did we get here? Where are we going?].
    Badimón JJ; Santos-Gallego CG; Badimón L
    Rev Esp Cardiol; 2010 Jun; 63 Suppl 2():20-35. PubMed ID: 20540898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HDL elevators and mimetics--emerging therapies for atherosclerosis.
    Pal M; Pillarisetti S
    Cardiovasc Hematol Agents Med Chem; 2007 Jan; 5(1):55-66. PubMed ID: 17266548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy.
    Rosenson RS
    Am Heart J; 2006 Mar; 151(3):556-63. PubMed ID: 16504615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice.
    Hansen MK; McVey MJ; White RF; Legos JJ; Brusq JM; Grillot DA; Issandou M; Barone FC
    J Cardiovasc Pharmacol Ther; 2010 Jun; 15(2):196-202. PubMed ID: 20332533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of cholesteryl ester transfer protein, peroxisome proliferator-activated receptor alpha, apolipoprotein E, and apolipoprotein A-I polymorphisms on high-density lipoprotein cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I:A-II concentrations: the Prospective Epidemiological Study of Myocardial Infarction study.
    Do HQ; Nazih H; Luc G; Arveiler D; Ferrières J; Evans A; Amouyel P; Cambien F; Ducimetière P; Bard JM
    Metabolism; 2009 Mar; 58(3):283-9. PubMed ID: 19217440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacotherapy for dyslipidaemia--current therapies and future agents.
    Bays H; Stein EA
    Expert Opin Pharmacother; 2003 Nov; 4(11):1901-38. PubMed ID: 14596646
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of high-density lipoprotein cholesterol in the prevention and possible treatment of cardiovascular diseases.
    Choi BG; Vilahur G; Yadegar D; Viles-Gonzalez JF; Badimon JJ
    Curr Mol Med; 2006 Aug; 6(5):571-87. PubMed ID: 16918377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular disease and dyslipidemia: beyond LDL.
    Pöss J; Custodis F; Werner C; Weingärtner O; Böhm M; Laufs U
    Curr Pharm Des; 2011; 17(9):861-70. PubMed ID: 21418031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.